-+ 0.00%
-+ 0.00%
-+ 0.00%

Camp4 expects SYNGAP1 therapy CMP-002 to enter Phase 1/2 trial in H2 2026

PUBT·04/28/2026 12:11:33
Listen to the news
Camp4 expects SYNGAP1 therapy CMP-002 to enter Phase 1/2 trial in H2 2026
  • Camp4 Therapeutics submitted a bioRxiv preprint on April 28, 2026 outlining its regulatory RNA profiling platform and antisense approach to raise expression of disease-relevant genes.
  • Results were presented in the preprint now, with no separate future presentation disclosed.
  • Preclinical work described ASOs that lifted OTC gene expression in human liver cells, supporting a potential treatment strategy for OTC deficiency.
  • Camp4 also flagged CMP-002 as lead candidate for SYNGAP1, with plans to start a Phase 1/2 trial in second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camp4 Therapeutics Corporation published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.